Kelly L Schoenbeck1, Mark A Fiala2, Tanya M Wildes3. 1. University of California San Francisco, San Francisco, CA, United States of America. Electronic address: kelly.schoenbeck@ucsf.edu. 2. Washington University School of Medicine, St Louis, MO, United States of America; Saint Louis University, St Louis, MO, United States of America. 3. Washington University School of Medicine, St Louis, MO, United States of America.
Abstract
BACKGROUND: Bortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls. The relationship between bortezomib and falls in older patients with multiple myeloma is unknown. METHODS: We analyzed the SEER-Medicare database for patients aged 65 or older diagnosed with multiple myeloma between 2007 and 2013. Claims were analyzed for myeloma treatments, falls, and covariates of interest. We evaluated accidental falls occurring within 12 months after starting first-line multiple myeloma treatment with bortezomib. RESULTS: Bortezomib was used in first-line therapy for 2052 older adults with new diagnoses of multiple myeloma. Claims for falls were reported in 157 (8%) patients within 12 months after starting bortezomib, compared to 102 (5%) patients not receiving bortezomib (p < 0.001). Bortezomib was associated with a 36% increased risk of falls after controlling for covariates (aHR 1.36; 95% CI 1.05-1.75; p = 0.018). In a landmark analysis of those who survived 12 months after starting treatment, the median overall survival of those with a fall was 35.7 months compared to 49.1 months for those without (p < 0.0001). A fall in the first year after diagnosis was associated with a 26% increased risk in hazard for death (aHR 1.26; 95% CI 1.02-1.56; p = 0.033). CONCLUSION: In older adults with multiple myeloma, bortezomib was associated with an increased risk of having a diagnostic code for falls. Decreased overall survival was seen in those who fell within the year of starting therapy. Prospective trials involving fall assessments and fall-prevention interventions are needed in this population.
BACKGROUND: Bortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls. The relationship between bortezomib and falls in older patients with multiple myeloma is unknown. METHODS: We analyzed the SEER-Medicare database for patients aged 65 or older diagnosed with multiple myeloma between 2007 and 2013. Claims were analyzed for myeloma treatments, falls, and covariates of interest. We evaluated accidental falls occurring within 12 months after starting first-line multiple myeloma treatment with bortezomib. RESULTS: Bortezomib was used in first-line therapy for 2052 older adults with new diagnoses of multiple myeloma. Claims for falls were reported in 157 (8%) patients within 12 months after starting bortezomib, compared to 102 (5%) patients not receiving bortezomib (p < 0.001). Bortezomib was associated with a 36% increased risk of falls after controlling for covariates (aHR 1.36; 95% CI 1.05-1.75; p = 0.018). In a landmark analysis of those who survived 12 months after starting treatment, the median overall survival of those with a fall was 35.7 months compared to 49.1 months for those without (p < 0.0001). A fall in the first year after diagnosis was associated with a 26% increased risk in hazard for death (aHR 1.26; 95% CI 1.02-1.56; p = 0.033). CONCLUSION: In older adults with multiple myeloma, bortezomib was associated with an increased risk of having a diagnostic code for falls. Decreased overall survival was seen in those who fell within the year of starting therapy. Prospective trials involving fall assessments and fall-prevention interventions are needed in this population.
Authors: Antonio Palumbo; Sara Bringhen; Maria-Victoria Mateos; Alessandra Larocca; Thierry Facon; Shaji K Kumar; Massimo Offidani; Philip McCarthy; Andrea Evangelista; Sagar Lonial; Sonja Zweegman; Pellegrino Musto; Evangelos Terpos; Andrew Belch; Roman Hajek; Heinz Ludwig; A Keith Stewart; Philippe Moreau; Kenneth Anderson; Hermann Einsele; Brian G M Durie; Meletios A Dimopoulos; Ola Landgren; Jesus F San Miguel; Paul Richardson; Pieter Sonneveld; S Vincent Rajkumar Journal: Blood Date: 2015-01-27 Impact factor: 22.113
Authors: Tanya M Wildes; Sascha A Tuchman; Heidi D Klepin; Joseph Mikhael; Kathryn Trinkaus; Keith Stockerl-Goldstein; Ravi Vij; Graham Colditz Journal: J Am Geriatr Soc Date: 2018-12-13 Impact factor: 5.562
Authors: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel Journal: Br J Haematol Date: 2009-01-16 Impact factor: 6.998
Authors: Elizabeth K O'Donnell; Jacob P Laubach; Andrew J Yee; Tianqi Chen; Carol Ann Huff; Frank G Basile; Philip M Wade; Claudia E Paba-Prada; Irene M Ghobrial; Robert L Schlossman; Jill N Burke; Cynthia C Harrington; Kathleen J Lively; Hannah F Lyons; Nikhil C Munshi; Kenneth C Anderson; Lorenzo Trippa; Paul G Richardson; Noopur S Raje Journal: Br J Haematol Date: 2018-05-08 Impact factor: 6.998
Authors: I Carrière; A Farré; J Norton; M Wyart; C Tzourio; P Noize; K Pérès; A Fourrier-Réglat; M L Ancelin Journal: Osteoporos Int Date: 2016-06-16 Impact factor: 4.507